The latest update is out from ArriVent BioPharma, Inc. (AVBP).
ArriVent BioPharma, Inc. has appointed Dr. John Hohneker, an experienced biotech leader with a robust background in pharmaceuticals, to its board as a Class II Director. Dr. Hohneker, with past executive roles at Anokion SA, Forma Therapeutics, and 14 years at Novartis AG, will serve on the board until the 2026 annual stockholders’ meeting. His appointment is part of a strategic move by the company, with Dr. Hohneker also set to receive standard non-employee director compensation, including a significant initial stock option award and an annual cash retainer.
For a thorough assessment of AVBP stock, go to TipRanks’ Stock Analysis page.
